20110168.TNBC
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.460
- ALLOGRAFT_REJECTION+0.300
- TNFA_SIGNALING_VIA_NFKB+0.290
- IL6_JAK_STAT3_SIGNALING+0.270
- MITOTIC_SPINDLE+0.200
- E2F_TARGETS+0.190
- INFLAMMATORY_RESPONSE+0.190
- MYC_TARGETS_V2+0.160
- G2M_CHECKPOINT+0.150
Top 10 suppressed
- PROTEIN_SECRETION-0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- OXIDATIVE_PHOSPHORYLATION-0.450
- ANDROGEN_RESPONSE-0.390
- ESTROGEN_RESPONSE_EARLY-0.370
- MYC_TARGETS_V1-0.360
- NOTCH_SIGNALING-0.360
- ADIPOGENESIS-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.340
- ANGIOGENESIS-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-A4PA-01A-11R-A24Z-07 | — | cohortMD2 | 0.848 |
| 2 | TCGA-LL-A441-01A-11R-A24H-07 | — | D | 0.830 |
| 3 | SRR8613797 | — | D | 0.828 |
| 4 | AUR-AG0J-TTP1-A-1-0-R-A741-41 | — | D | 0.827 |
| 5 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.822 |
| 6 | SRR5088835 | — | — | 0.810 |
| 7 | TCGA-AO-A0JC-01A-11R-A056-07 | — | D | 0.805 |
| 8 | s0095135 | — | — | 0.804 |
| 9 | SRR5088834 | — | — | 0.802 |
| 10 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| HYPOXIA | 0.030 | Idelalisib | — uncovered |